SCHEMBL269317

SCHEMBL269317

O=C(Nc1ccc(N2CCCCC2)cc1C(=O)NN=Cc1ccc(F)cc1)c1cccc(CN2CCC(O)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
ABCB1 P08183 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
ENPP2 Q13822 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269316 1.00 SLC34A2 (0.48) SLC34A2L3MBTL1CYP1A2CYP2D6MAPT
SCHEMBL267467 0.93 SLC34A2 (0.49) SLC34A2CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL267466 0.93 SLC34A2 (0.49) SLC34A2CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL266819 0.93 SLC34A2 (0.47) SLC34A2MAPTCYP2C9MEN1RAB9A
SCHEMBL266820 0.93 SLC34A2 (0.47) SLC34A2MAPTCYP2C9MEN1RAB9A
SCHEMBL267911 0.91 MAPT (0.47) SLC34A2L3MBTL1MAPTCYP2C9MEN1
SCHEMBL267910 0.91 MAPT (0.47) SLC34A2L3MBTL1MAPTCYP2C9MEN1
SCHEMBL270102 0.90 SLC34A2 (0.48) SLC34A2CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL270103 0.90 SLC34A2 (0.48) SLC34A2CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL267519 0.90 MAPT (0.45) SLC34A2L3MBTL1CYP1A2CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885L3MBTL1 934/4885CYP1A2 1686/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885L3MBTL1 1096/4885CYP1A2 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.